Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing (NGS) solutions for over two decades. Today, we are proud to announce that we have been included in the esteemed Inc. 5000 List of rapidly growing American companies. Out of the 6 million businesses in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year—an achievement that reflects our continued growth, innovation, and global impact in genomics.
Being ranked in the Inc. 5000 List, Golden Helix is among some of the fastest growing and highly respected companies in both size and revenue – a testament to the company’s focus on innovation, quality, and customer satisfaction.
We are ecstatic to be named among the country’s leading companies. Next-Generation Sequencing is here to stay, and we are very appreciative to be experiencing global adoption of our solution stack. Our industry-leading CNV analytics capabilities in conjunction with state-of-the-art clinical workflows to diagnose cancer and rare diseases have differentiated ourselves in the marketplace. On top of that, we provide secure and scalable enterprise deployment capabilities with our data warehouse solution.
Of the tens of thousands of companies that have applied over the years, only a fraction of them makes the list more than once. The recognition comes on the heels of Golden Helix also being recognized by Healthcare Tech Outlook on its list of Top 10 Genetic Diagnostics Companies of 2020.
The whole team at Golden Helix would like to thank each of our customers and partners for helping us become one of the fastest-growing biotech firms in the country. I also want to thank the entire team at Golden Helix for all the creativity and dedication over many years in a competitive marketplace. We’re honored to receive this recognition among so many remarkable companies.
